Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 9/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19920982 | 0.80 | CHRNB2 (0.45) | RAB9AKMT2AKDM4ENPC1MAPK1 | |
| SCHEMBL1421510 | 0.78 | RAB9A (0.54) | RAB9AKMT2AKDM4ENPC1ALDH1A1 | |
| SCHEMBL1814015 | 0.77 | RAB9A (0.56) | RAB9ACYP1A2KMT2ANPC1ALDH1A1 | |
| SCHEMBL25346779 | 0.76 | RAB9A (0.62) | RAB9ACYP1A2KMT2AKDM4ENPC1 | |
| SCHEMBL12094958 | 0.76 | NPC1 (0.53) | RAB9AKMT2ANPC1MAPK1SMN1; SMN2 | |
| SCHEMBL2773834 | 0.75 | SMN1; SMN2 (0.64) | RAB9ACYP1A2KMT2AKDM4ENPC1 | |
| SCHEMBL1808893 | 0.74 | RIOK2 (0.45) | RAB9AKMT2AKDM4ENPC1ALDH1A1 | |
| SCHEMBL20474443 | 0.73 | MEN1 (0.33) | RAB9AKMT2ANPC1ALDH1A1MEN1 | |
| SCHEMBL21892294 | 0.73 | RAB9A (0.59) | RAB9ACYP1A2KMT2AKDM4ENPC1 | |
| SCHEMBL7930791 | 0.73 | RAB9A (0.62) | RAB9ACYP1A2KMT2AKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551980-B2 | Substituted triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-20120328611-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| EP-2343294-A1 | Substituted triazolopyridines | Bayer Schering Pharma AG (DE) | 2011-07-13 | — | — | EP | disclosed |
| WO-2011063907-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120328611-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | TTBK1, TTK, BUB1 | RAB9A 2351/4885CYP1A2 1917/4885KMT2A 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.